Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06755632Recruiting
Hepatic fibrosis or cirrhosis screening trial
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
BobignyAges 18 years+ - NCT06703450Enrolling by invitation
Liver fibrosis study with MRI for MASLD patients
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
New York, New YorkAges 18–89 - NCT06697509Enrolling by invitation
Better heart scar detection with MRI
This study tests a new way to use heart MRI to find scarring (fibrosis) in the heart muscle. It may help doctors detect heart damage more accurately.
Lørenskog, NorgeAges 18 years+ - NCT06683092Recruiting
Restarting triple therapy with close monitoring for side effects
This trial tests whether carefully restarting a triple-combination CFTR modulator (VTD) is safe and helpful for people with cystic fibrosis who had to stop or change Trikafta because of mental health side effects or liver injury. You will be closely monitored with surveys and daily diaries to ensure your safety.
Birmingham, AlabamaAges 6 years+ - NCT06242795RecruitingPhase 4
Hypertonic saline for non-cystic fibrosis bronchiectasis
This trial tests whether inhaling a saltwater solution (hypertonic saline) twice a day for 12 weeks can help people with bronchiectasis who have a chronic cough and have had flare-ups in the past. It aims to see if this treatment reduces mucus and improves quality of life.
Chapel Hill, North CarolinaAges 18 years+ - NCT06655480RecruitingPhase 2
Triple drug therapy for advanced heart failure with preserved ejection fraction
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
MoscowAges 40–80 - NCT06654752Recruiting
Simpler treatment for lung flare-ups in kids with CF
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
Birmingham, AlabamaAges 3–18 - NCT06619106Recruiting
Screening tool for minimal hepatic encephalopathy
This study tests a new cognitive tool to quickly and reliably detect minimal hepatic encephalopathy, a subtle brain change that can occur in people with liver disease. If you have a liver condition like fibrosis or cirrhosis and are already scheduled for a full evaluation (neuropsychological tests, MRI, EEG, and blood ammonia), this tool could help simplify future screening.
ParisAges 18–70 - NCT06603246RecruitingPhase 1
Study of inhaled GDC-6988 for mucus lung diseases
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
Birmingham, AlabamaAges 18 years+ - NCT06615492Recruiting
Lung transplant study: comparing two ECMO methods
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06592820Recruiting
Ultrasound stiffness test for fatty liver disease
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
Boston, MassachusettsAges 18 years+ - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT06567990Recruiting
Type 2 diabetes and fatty liver: new tests for disease tracking
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
DijonAges 40–80 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT06516237Recruiting
New imaging for fibrosis in ulcerative colitis
This study looks at new ways to detect scarring (fibrosis) in the bowel using advanced imaging and tests. It may help doctors better understand and monitor ulcerative colitis. If you are already having a colonoscopy, you may be able to join.
Milan, LombardyAges 18 years+ - NCT05490888RecruitingPhase 1
Dose study of PHIN-214 for mild to moderate cirrhosis
This Phase 1 study tests how the medicine PHIN-214 behaves in the body and what dose is tolerable in people with Child-Pugh A or B liver cirrhosis. It may help doctors plan safer dosing for future studies.
Chandler, ArizonaAges 18–75 - NCT06504589Recruiting
Study for CF treatments for people without modulators
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
Birmingham, AlabamaAges 12 years+ - NCT06512064Recruiting
Breath sound analysis for lung health
This study tests a new device that listens to your breathing to check how well your lungs are working. It might help diagnose lung conditions without the need for forceful blowing tests, making it easier for patients.
Indianapolis, IndianaAges 8–70 - NCT06463223Enrolling by invitation
Liver imaging study for children with obesity
This study uses MRI scans to look at the livers of children with obesity, to find early signs of liver problems. It may help doctors understand how to protect the liver in children.
Gothenburg, Västra Götaland CountyAges 9–14 - NCT06409585Recruiting
Heart muscle disease imaging study for scarring
This study uses advanced imaging (PET/MR or PET/CT) to look at scarring (fibrosis) in the heart muscle. It is for people with various heart muscle diseases, including heart failure with preserved pumping, thickened heart muscle, high blood pressure-related heart damage, heart inflammation, and others.
Edinburgh, ScotlandAges 30–90 - NCT06339593RecruitingEarly Phase 1
Using MRI to Monitor CF Lung Health
This study uses MRI scans to monitor lung health in teens and young adults with cystic fibrosis who are taking Trikafta. It aims to find better ways to track how the disease affects the lungs over time.
Cincinnati, OhioAges 12–21 - NCT06341166Recruiting
Predicting heart scarring in mitral valve prolapse
This study looks at people with mitral valve prolapse (a common heart valve condition) to see if doctors can predict who might have scar tissue in their heart muscle. If you have this condition, joining could help improve understanding of your heart health.
Milan, MilanAges 18 years+ - NCT06325696RecruitingPhase 2
H01 for adults with lung scarring (SOLIS study)
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Research Triangle Park, North CarolinaAges 18–100 - NCT06273566Recruiting
Validating a questionnaire for adults with cystic fibrosis
This study is checking if a French questionnaire about physical therapy and daily life works well for people with cystic fibrosis. You would answer questions to help doctors better understand your experience.
CaenAges 18–100
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 417 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.